Phase 1 × Recruiting × Squamous Cell Carcinoma of Head and Neck × Clear all A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Phase 1 Recruiting
90 enrolled
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
LUMIRAY
Phase 1 Recruiting
30 enrolled
STELLAR-002
Phase 1 Recruiting
1,314 enrolled
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
Phase 1 Recruiting
24 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
46 enrolled
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Phase 1 Recruiting
40 enrolled
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 Recruiting
714 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Phase 1 Recruiting
170 enrolled
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Phase 1 Recruiting
220 enrolled
GUARDIAN-101
Phase 1 Recruiting
90 enrolled
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase 1 Recruiting
150 enrolled
EXCEED
Phase 1 Recruiting
490 enrolled
VISTA
Phase 1 Recruiting
45 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled
Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
Phase 1 Recruiting
45 enrolled
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Phase 1 Recruiting
470 enrolled
SIM0610-101
Phase 1 Recruiting
260 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
Phase 1 Recruiting
41 enrolled
A Study of DM005 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
136 enrolled
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
145 enrolled
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Phase 1 Recruiting
22 enrolled
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Phase 1 Recruiting
16 enrolled
ON-5001
Phase 1 Recruiting
168 enrolled
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 Recruiting
248 enrolled
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
158 enrolled
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Phase 1 Recruiting
60 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 Recruiting
73 enrolled
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 Recruiting
310 enrolled
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 Recruiting
56 enrolled
LB-LR1109
Phase 1 Recruiting
76 enrolled
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
Phase 1 Recruiting
12 enrolled
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Phase 1 Recruiting
10 enrolled
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
Phase 1 Recruiting
11 enrolled
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Phase 1 Recruiting
512 enrolled
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 Recruiting
54 enrolled
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Phase 1 Recruiting
130 enrolled
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
Phase 1 Recruiting
40 enrolled
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Phase 1 Recruiting
40 enrolled
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Phase 1 Recruiting
21 enrolled
A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 Recruiting
345 enrolled
INVOKE
Phase 1 Recruiting
166 enrolled
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Phase 1 Recruiting
292 enrolled
Study of CHS-114 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
87 enrolled
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Phase 1 Recruiting
241 enrolled